SilkMatrix Wound™ takes the silk scaffold technology already fabricated by the founder and adapts it into a bioactive, breathable wound-healing matrix — one validated platform, a second clinical market.
The properties that make silk a good scaffold — bioactivity, a fine porous structure, and gentle resorption — are exactly what an advanced wound matrix needs. Rather than just covering a wound, the matrix is designed to support the body’s own repair.
SilkMatrix Wound™ and SilkMatrix Scaffold™ are not two separate bets — they are one material platform pointed at two different clinical needs. Every step that validates the scaffold strengthens the wound matrix, and vice-versa.
The same silk-fibroin know-how underpins both products — one R&D effort, two outputs.
A new market reached by reformatting proven science — not by starting over.
Wholly-owned IP across formats deepens the venture’s defensible position.
Silk proteins combine bioactivity with tunable, resorbable structure — a rare pairing for a material that sits directly against healing tissue.
The wound line is in formulation and design, advancing on the shoulders of the scaffold and lead-fixation work.
Leverages the silk scaffold technology the founder has already fabricated.
Defining the wound-matrix format, structure and resorption profile.
Sequenced to follow the platform’s core validation milestones.
The multi-market expansion logic, work packages and milestones are shared under confidentiality with qualified investors and advisors.